Pasar al contenido principal

RNA BINDING PROTEINS IN TRANSLATION AND METASTASIS

PGC2018-099697-B-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de Generación de Conocimiento y Fortalecimiento Científico y Tecnológico del Sistema de I+D+i
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D (Excelencia / Generación de Conocimiento)
Año convocatoria 2018
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACIO CENTRE DE REGULACIO GENOMICA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 18
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Melanoma RBPome identification reveals PDIA6 as an unconventional RNA-binding protein involved in metastasis

  • Mestre-Farràs, Neus
  • Guerrero Jijon, Santiago Xavier
  • Bley, Nadine
  • Rivero, Ezequiel
  • Coll, Olga
  • Borràs, Eva
  • Sabidó Aguadé, Eduard, 1981-
  • Indacochea Cusirramos, Alberto
  • Casillas-Serra, Carlos
  • Järvelin, Aino I.
  • Oliva Miguel, Baldomero
  • Castello, Alfredo
  • Hüttelmaier, Stefan
  • Gebauer, Fátima
RNA-binding proteins (RBPs) have been relatively overlooked in cancer research despite their contribution to virtually every cancer hallmark. Here, we use RNA interactome capture (RIC) to characterize the melanoma RBPome and uncover novel RBPs involved in melanoma progression. Comparison of RIC profiles of a non-tumoral versus a metastatic cell line revealed prevalent changes in RNA-binding capacities that were not associated with changes in RBP levels. Extensive functional validation of a selected group of 24 RBPs using five different in vitro assays unveiled unanticipated roles of RBPs in melanoma malignancy. As proof-of-principle we focused on PDIA6, an ER-lumen chaperone that displayed a novel RNA-binding activity. We show that PDIA6 is involved in metastatic progression, map its RNA-binding domain, and find that RNA binding is required for PDIA6 tumorigenic properties. These results exemplify how RIC technologies can be harnessed to uncover novel vulnerabilities of cancer cells., N.M. was supported by an FPI fellowship from the Ministry of Economy and Competitiveness; F.G. was supported by national grants BFU2015-68741-P from MINECO, PGC2018-099697-B-I00 from MICINN, ‘la Caixa’ Foundation [100010434] under the agreement LCF/PR/HR17/52150016, Marató-TV3 Foundation [20131430]; Catalan Agency for Research and Universities [2017SGR534]; CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech) and it is member of ProteoRed PRB3 consortium which is supported by grant PT17/0019 of the PE I + D + i 2013–2016 from the Instituto de Salud Carlos III (ISCIII), ERDF, and ‘Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya’ [2017SGR595]. A.C. is funded by the MRC Career Development Award (MR/L019434/1) and the ERC Consolidator 101001634 vRNP-capture. We acknowledge the support of the Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa (CEX2020-001049-S, MCIN/AEI /10.13039/501100011033), and the Generalitat de Catalunya through the CERCA Programme. Funding for open access charge: MINECO [PGC2018-099697-B-I00].
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Melanoma RBPome identification reveals PDIA6 as an unconventional RNA-binding protein involved in metastasis

  • Mestre-Farràs, Neus
  • Guerrero Jijon, Santiago Xavier
  • Bley, Nadine
  • Rivero, Ezequiel
  • Coll, Olga
  • Borràs, Eva
  • Sabidó Aguadé, Eduard, 1981-
  • Indacochea Cusirramos, Alberto
  • Casillas-Serra, Carlos
  • Järvelin, Aino I.
  • Oliva Miguel, Baldomero
  • Castello, Alfredo
  • Hüttelmaier, Stefan
  • Gebauer, Fátima
RNA-binding proteins (RBPs) have been relatively overlooked in cancer research despite their contribution to virtually every cancer hallmark. Here, we use RNA interactome capture (RIC) to characterize the melanoma RBPome and uncover novel RBPs involved in melanoma progression. Comparison of RIC profiles of a non-tumoral versus a metastatic cell line revealed prevalent changes in RNA-binding capacities that were not associated with changes in RBP levels. Extensive functional validation of a selected group of 24 RBPs using five different in vitro assays unveiled unanticipated roles of RBPs in melanoma malignancy. As proof-of-principle we focused on PDIA6, an ER-lumen chaperone that displayed a novel RNA-binding activity. We show that PDIA6 is involved in metastatic progression, map its RNA-binding domain, and find that RNA binding is required for PDIA6 tumorigenic properties. These results exemplify how RIC technologies can be harnessed to uncover novel vulnerabilities of cancer cells., N.M. was supported by an FPI fellowship from the Ministry of Economy and Competitiveness; F.G. was supported by national grants BFU2015-68741-P from MINECO, PGC2018-099697-B-I00 from MICINN, ‘la Caixa’ Foundation [100010434] under the agreement LCF/PR/HR17/52150016, Marató-TV3 Foundation [20131430]; Catalan Agency for Research and Universities [2017SGR534]; CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech) and it is member of ProteoRed PRB3 consortium which is supported by grant PT17/0019 of the PE I + D + i 2013–2016 from the Instituto de Salud Carlos III (ISCIII), ERDF, and ‘Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya’ [2017SGR595]. A.C. is funded by the MRC Career Development Award (MR/L019434/1) and the ERC Consolidator 101001634 vRNP-capture. We acknowledge the support of the Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa (CEX2020-001049-S, MCIN/AEI /10.13039/501100011033), and the Generalitat de Catalunya through the CERCA Programme. Funding for open access charge: MINECO [PGC2018-099697-B-I00].
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Coordinated post-transcriptional control of oncogene-induced senescence by UNR/CSDE1

  • Avolio, Rosario
  • Inglés Ferrándiz, Marta, 1989-
  • Ciocia, Annagiulia
  • Coll, Olga
  • Bonnin, Sarah
  • Guitart, Tanit
  • Ribó Rubio, Anna
  • Gebauer, Fátima
Oncogene-induced senescence (OIS) is a form of stable cell-cycle arrest arising in response to oncogenic stimulation. OIS must be bypassed for transformation, but the mechanisms of OIS establishment and bypass remain poorly understood, especially at the post-transcriptional level. Here, we show that the RNA-binding protein UNR/CSDE1 enables OIS in primary mouse keratinocytes. Depletion of CSDE1 leads to senescence bypass, cell immortalization, and tumor formation, indicating that CSDE1 behaves as a tumor suppressor. Unbiased high-throughput analyses uncovered that CSDE1 promotes OIS by two independent molecular mechanisms: enhancement of the stability of senescence-associated secretory phenotype (SASP) factor mRNAs and repression of Ybx1 mRNA translation. Importantly, depletion of YBX1 from immortal keratinocytes rescues senescence and uncouples proliferation arrest from the SASP, revealing multilayered mechanisms exerted by CSDE1 to coordinate senescence. Our data highlight the relevance of post-transcriptional control in the regulation of senescence., We thank Bill Keyes and members of his lab Mekayla Storer, Birgit Ritschka, and Alba Mas for expert advice and help at the initial stages of this project. We also thank Jernej Ule for sharing reagents and expertise on iCLIP, Ola Larsson for guidance on anota2seq, and Bill Keyes and Juan Valcárcel for carefully reading the manuscript. We acknowledge Raquel García Olivas of the CRG Advanced Light Microscopy Unit (ALMU) for her support and assistance in this work. We thank the CRG Bioinformatics Unit, the CRG Genomics Facility, the CRG/UPF FACS Unit, and the IRB Histopathology Facility for high-throughput sequencing and analysis, cell sorting, and histopathology analysis, respectively. M.I.-F. and A.C. were supported by FPI fellowships from the Spanish Ministry of Science and Innovation (MICINN) . F.G. was supported by grants from MICINN ( PGC2018-099697-B-I00 and BFU2015-68741 ), “La Caixa” Foundation (ID 100010434 ) under the agreement LCF/PR/HR17/52150016, the Catalan Agency for Research and Universities ( 2017SGR534 ), and the Centre of Excellence Severo Ochoa.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

ADAR3 modulates neuronal differentiation and regulates mRNA stability and translation

  • Karlström, Victor
  • Sagredo, Eduardo A.
  • Planells, Jordi
  • Welinder, Charlotte
  • Jungfleisch, Jennifer
  • Barrera Conde, Andrea
  • Engfors, Linus
  • Daniel, Chammiran
  • Gebauer, Fátima
  • Visa, Neus
  • Öhman, Marie
ADAR3 is a catalytically inactive member of the family of adenosine deaminases acting on RNA (ADARs). Here we have investigated its function in the context of the developing mouse brain. The expression of ADAR3 gradually increases throughout embryogenesis and drops after birth. Using primary cortical neurons, we show that ADAR3 is only expressed in a subpopulation of in vitro differentiated neurons, which suggests specific functions rather than being a general regulator of ADAR editing in the brain. The analysis of the ADAR3 interactome suggested a role in mRNA stability and translation, and we show that expression of ADAR3 in a neuronal cell line that is otherwise ADAR3-negative changes the expression and stability of a large number of mRNAs. Notably, we show that ADAR3 associates with polysomes and inhibits translation. We propose that ADAR3 binds to target mRNAs and stabilizes them in non-productive polysome complexes. Interestingly, the expression of ADAR3 downregulates genes related to neuronal differentiation and inhibits neurofilament outgrowth in vitro. In summary, we propose that ADAR3 negatively regulates neuronal differentiation, and that it does so by regulating mRNA stability and translation in an editing-independent manner., Swedish Research Council [dnr.2016-02005, 2018-03823, 2019-03853 to M.Ö., C.D., N.V.]; Carl Trygger's Foundation (to N.V.); V.K. and J.P.R. were supported by the Department of Molecular Biosciences, Wenner-Gren Institute, Stockholm University; E.A.S. was supported by SFO funding from the Faculty of Science at the Stockholm University, O.E. and Edla Johanssons Foundation and Royal Physiographic Society in Lund; Spanish Ministry of Science and Innovation [PGC2018-099697-B-I00 and PID2021-127948NB-I00 to F.G.]; Centro de Excelencia Severo Ochoa [CEX2020-001049-S, MCIN/AEI /10.13039/501100011033]; Generalitat de Catalunya through the CERCA Programme.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Cold-inducible RNA binding protein promotes breast cancer cell malignancy by regulating Cystatin C levels

  • Indacochea Cusirramos, Alberto
  • Guerrero Jijon, Santiago Xavier
  • Ureña, Macarena
  • Araujo, Ferrán
  • Coll, Olga
  • Lleonart, Matilde E.
  • Gebauer, Fátima
Cold-inducible RNA binding protein (CIRBP) is a stress-responsive protein that promotes cancer development and inflammation. Critical to most CIRBP functions is its capacity to bind and posttranscriptionally modulate mRNA. However, a transcriptome-wide analysis of CIRBP mRNA targets in cancer has not yet been performed. Here, we use an ex vivo breast cancer model to identify CIRBP targets and mechanisms. We find that CIRBP transcript levels correlate with breast cancer subtype and are an indicator of luminal A/B prognosis. Accordingly, overexpression of CIRBP in nontumoral MCF-10A cells promotes cell growth and clonogenicity, while depletion of CIRBP from luminal A MCF-7 cells has opposite effects. We use RNA immunoprecipitation followed by high-throughput sequencing (RIP-seq) to identify a set of 204 high confident CIRBP targets in MCF-7 cells. About 10% of these showed complementary changes after CIRBP manipulation in MCF-10A and MCF-7 cells, and were highly interconnected with known breast cancer genes. To test the potential of CIRBP-mediated regulation of these targets in breast cancer development, we focused on Cystatin C (CST3), one of the most highly interconnected genes, encoding a protein that displays tumor suppressive capacities. CST3 depletion restored the effects of CIRBP depletion in MCF-7 cells, indicating that CIRBP functions, at least in part, by down-regulating CST3 levels. Our data provide a resource of CIRBP targets in breast cancer, and identify CST3 as a novel downstream mediator of CIRBP function., Funding: A.I. was supported by a CRG PhD4MD fellowship. F.G. was supported by grants from the Spanish Ministry of Science and Innovation (MICINN, PGC2018-099697-B-I00), “la Caixa” Foundation (ID 100010434) under the agreement LCF/PR/HR17/52150016, the Catalan Agency for Research and Universities (2017SGR534), and the Centre of Excellence Severo Ochoa. M.E.LL. was supported by grants from the Instituto de Salud Carlos III:PI15/01262 and CP03/00101 cofinanced by the European Regional Fund (ERDF) and AECC Funding ref. GC16173720CARR
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

RNA-binding proteins in human genetic disease

  • Gebauer, Fátima
  • Schwarzl, Thomas
  • Valcárcel, J. (Juan)
  • Hentze, Matthias W.
RNA-binding proteins (RBPs) are critical effectors of gene expression, and as such their malfunction underlies the origin of many diseases. RBPs can recognize hundreds of transcripts and form extensive regulatory networks that help to maintain cell homeostasis. System-wide unbiased identification of RBPs has increased the number of recognized RBPs into the four-digit range and revealed new paradigms: from the prevalence of structurally disordered RNA-binding regions with roles in the formation of membraneless organelles to unsuspected and potentially pervasive connections between intermediary metabolism and RNA regulation. Together with an increasingly detailed understanding of molecular mechanisms of RBP function, these insights are facilitating the development of new therapies to treat malignancies. Here, we provide an overview of RBPs involved in human genetic disorders, both Mendelian and somatic, and discuss emerging aspects in the field with emphasis on molecular mechanisms of disease and therapeutic interventions., The authors acknowledge funding from the Spanish Ministry of Science and Innovation (MICINN; PGC2018-099697-B-I00 to F.G. and BFU2017-89308-P to J.V.), ‘la Caixa’ Foundation (ID 100010434 under the agreement LCF/PR/HR17/52150016 to F.G.), the Catalan Government (2017SGR534 to F.G. and J.V.) and the ERC (AdvG 670146 to J.V.) as well as the EMBL Partnership, the Severo Ochoa and CERCA Programs
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

CSDE1 intracellular distribution as a biomarker of melanoma prognosis

  • Indacochea Cusirramos, Alberto
  • Guitart, Tanit
  • Boada, Aram
  • Peg, Vicente
  • Quer, Ariadna
  • Laayouni, Hafid, 1968-
  • Condal, Laura
  • Espinosa, Pablo
  • Manzano Mozo, José Luis
  • Gebauer, Fátima
RNA-binding proteins are emerging as critical modulators of oncogenic cell transformation, malignancy and therapy resistance. We have previously found that the RNA-binding protein Cold Shock Domain containing protein E1 (CSDE1) promotes invasion and metastasis of melanoma, the deadliest form of skin cancer and also a highly heterogeneous disease in need of predictive biomarkers and druggable targets. Here, we design a monoclonal antibody useful for IHC in the clinical setting and use it to evaluate the prognosis potential of CSDE1 in an exploratory cohort of 149 whole tissue sections including benign nevi and primary tumors and metastasis from melanoma patients. Contrary to expectations for an oncoprotein, we observed a global decrease in CSDE1 levels with increasing malignancy. However, the CSDE1 cytoplasmic/nuclear ratio exhibited a positive correlation with adverse clinical features of primary tumors and emerged as a robust indicator of progression free survival in cutaneous melanoma, highlighting the potential of CSDE1 as a biomarker of prognosis. Our findings provide a novel feature for prognosis assessment and highlight the intricacies of RNA-binding protein dynamics in cancer progression., A.I. and P.E. were supported by PhD4MD fellowships from the CRG and the Emerald program (Marie Skłodowska-Curie grant agreement 101034290), respectively. This work was supported by the following grants to F.G.: PGC2018-099697-B-I00 and PID2021-127948NB-I00 from the Spanish Ministry of Science and Innovation (MCIN) funded by MCIN/ AEI /10.13039/501100011033/ and by ERDF; “la Caixa” Foundation (ID 100010434) under the Grant LCF/PR/HR17/52150016; the Catalan Agency for Research and Universities (SGR-Cat-2021-01215) and intramural funds from the CRG on emergent translational research. We acknowledge the support of the Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa (CEX2020-001049-S, MCIN/AEI /10.13039/501100011033) and the Generalitat de Catalunya through the CERCA programme.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Ataxin-2, Twenty-four, and Dicer-2 are components of a noncanonical cytoplasmic polyadenylation complex

  • Nadimpalli, Hima Priyanka, 1988-
  • Guitart, Tanit
  • Coll, Olga
  • Gebauer, Fátima
Cytoplasmic polyadenylation is a mechanism to promote mRNA translation in a wide variety of biological contexts. A canonical complex centered around the conserved RNA-binding protein family CPEB has been shown to be responsible for this process. We have previously reported evidence for an alternative noncanonical, CPEB-independent complex in Drosophila, of which the RNA-interference factor Dicer-2 is a component. Here, we investigate Dicer-2 mRNA targets and protein cofactors in cytoplasmic polyadenylation. Using RIP-Seq analysis, we identify hundreds of potential Dicer-2 target transcripts, ∼60% of which were previously found as targets of the cytoplasmic poly(A) polymerase Wispy, suggesting widespread roles of Dicer-2 in cytoplasmic polyadenylation. Large-scale immunoprecipitation revealed Ataxin-2 and Twenty-four among the high-confidence interactors of Dicer-2. Complex analyses indicated that both factors form an RNA-independent complex with Dicer-2 and mediate interactions of Dicer-2 with Wispy. Functional poly(A)-test analyses showed that Twenty-four and Ataxin-2 are required for cytoplasmic polyadenylation of a subset of Dicer-2 targets. Our results reveal components of a novel cytoplasmic polyadenylation complex that operates during Drosophila early embryogenesis., This work was supported by grants from the Spanish Ministry of Science and Innovation (PGC2018-099697-B-I00 and BFU2015-68741) and the Catalan Agency for Research and Universities (2017SGR534). We acknowledge the support of the Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa (CEX2020-001049-S, MCIN/AEI/10.13039/501100011033) and the Generalitat de Catalunya through the CERCA Programme.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

CSDE1 Intracellular Distribution as a Biomarker of Melanoma Prognosis

  • Indacochea, Alberto
  • Guitart, Tanit
  • Boada, Aram
  • Peg, Vicente
  • Quer, Ariadna
  • Laayouni, Hafid
  • Condal, Laura
  • Espinosa, Pablo
  • Manzano, José Luis
  • Gebauer, Fátima
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)., RNA-binding proteins are emerging as critical modulators of oncogenic cell transformation, malignancy and therapy resistance. We have previously found that the RNA-binding protein Cold Shock Domain containing protein E1 (CSDE1) promotes invasion and metastasis of melanoma, the deadliest form of skin cancer and also a highly heterogeneous disease in need of predictive biomarkers and druggable targets. Here, we design a monoclonal antibody useful for IHC in the clinical setting and use it to evaluate the prognosis potential of CSDE1 in an exploratory cohort of 149 whole tissue sections including benign nevi and primary tumors and metastasis from melanoma patients. Contrary to expectations for an oncoprotein, we observed a global decrease in CSDE1 levels with increasing malignancy. However, the CSDE1 cytoplasmic/nuclear ratio exhibited a positive correlation with adverse clinical features of primary tumors and emerged as a robust indicator of progression free survival in cutaneous melanoma, highlighting the potential of CSDE1 as a biomarker of prognosis. Our findings provide a novel feature for prognosis assessment and highlight the intricacies of RNA-binding protein dynamics in cancer progression., A.I. and P.E. were supported by PhD4MD fellowships from the CRG and the Emerald program (Marie Skłodowska-Curie grant agreement 101034290), respectively. This work was supported by the following grants to F.G.: PGC2018-099697-B-I00 and PID2021-127948NB-I00 from the Spanish Ministry of Science and Innovation (MCIN) funded by MCIN/ AEI /10.13039/501100011033/ and by ERDF; “la Caixa” Foundation (ID 100010434) under the Grant LCF/PR/HR17/52150016; the Catalan Agency for Research and Universities (SGR-Cat-2021-01215) and intramural funds from the CRG on emergent translational research. We acknowledge the support of the Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa (CEX2020-001049-S, MCIN/AEI /10.13039/501100011033) and the Generalitat de Catalunya through the CERCA programme., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2020-001049-S)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Coordinated post-transcriptional control of oncogene-induced senescence by UNR/CSDE1

  • Avolio, Rosario
  • Inglés Ferrándiz, Marta, 1989-
  • Ciocia, Annagiulia
  • Coll, Olga
  • Bonnin, Sarah
  • Guitart, Tanit
  • Ribó Rubio, Anna
  • Gebauer, Fátima
Oncogene-induced senescence (OIS) is a form of stable cell-cycle arrest arising in response to oncogenic stimulation. OIS must be bypassed for transformation, but the mechanisms of OIS establishment and bypass remain poorly understood, especially at the post-transcriptional level. Here, we show that the RNA-binding protein UNR/CSDE1 enables OIS in primary mouse keratinocytes. Depletion of CSDE1 leads to senescence bypass, cell immortalization, and tumor formation, indicating that CSDE1 behaves as a tumor suppressor. Unbiased high-throughput analyses uncovered that CSDE1 promotes OIS by two independent molecular mechanisms: enhancement of the stability of senescence-associated secretory phenotype (SASP) factor mRNAs and repression of Ybx1 mRNA translation. Importantly, depletion of YBX1 from immortal keratinocytes rescues senescence and uncouples proliferation arrest from the SASP, revealing multilayered mechanisms exerted by CSDE1 to coordinate senescence. Our data highlight the relevance of post-transcriptional control in the regulation of senescence., We thank Bill Keyes and members of his lab Mekayla Storer, Birgit Ritschka, and Alba Mas for expert advice and help at the initial stages of this project. We also thank Jernej Ule for sharing reagents and expertise on iCLIP, Ola Larsson for guidance on anota2seq, and Bill Keyes and Juan Valcárcel for carefully reading the manuscript. We acknowledge Raquel García Olivas of the CRG Advanced Light Microscopy Unit (ALMU) for her support and assistance in this work. We thank the CRG Bioinformatics Unit, the CRG Genomics Facility, the CRG/UPF FACS Unit, and the IRB Histopathology Facility for high-throughput sequencing and analysis, cell sorting, and histopathology analysis, respectively. M.I.-F. and A.C. were supported by FPI fellowships from the Spanish Ministry of Science and Innovation (MICINN) . F.G. was supported by grants from MICINN ( PGC2018-099697-B-I00 and BFU2015-68741 ), “La Caixa” Foundation (ID 100010434 ) under the agreement LCF/PR/HR17/52150016, the Catalan Agency for Research and Universities ( 2017SGR534 ), and the Centre of Excellence Severo Ochoa.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Melanoma RBPome identification reveals PDIA6 as an unconventional RNA-binding protein involved in metastasis

  • Mestre-Farràs, Neus
  • Guerrero Jijon, Santiago Xavier
  • Bley, Nadine
  • Rivero, Ezequiel
  • Coll, Olga
  • Borràs, Eva
  • Sabidó Aguadé, Eduard, 1981-
  • Indacochea Cusirramos, Alberto
  • Casillas-Serra, Carlos
  • Järvelin, Aino I.
  • Oliva Miguel, Baldomero
  • Castello, Alfredo
  • Hüttelmaier, Stefan
  • Gebauer, Fátima
RNA-binding proteins (RBPs) have been relatively overlooked in cancer research despite their contribution to virtually every cancer hallmark. Here, we use RNA interactome capture (RIC) to characterize the melanoma RBPome and uncover novel RBPs involved in melanoma progression. Comparison of RIC profiles of a non-tumoral versus a metastatic cell line revealed prevalent changes in RNA-binding capacities that were not associated with changes in RBP levels. Extensive functional validation of a selected group of 24 RBPs using five different in vitro assays unveiled unanticipated roles of RBPs in melanoma malignancy. As proof-of-principle we focused on PDIA6, an ER-lumen chaperone that displayed a novel RNA-binding activity. We show that PDIA6 is involved in metastatic progression, map its RNA-binding domain, and find that RNA binding is required for PDIA6 tumorigenic properties. These results exemplify how RIC technologies can be harnessed to uncover novel vulnerabilities of cancer cells., N.M. was supported by an FPI fellowship from the Ministry of Economy and Competitiveness; F.G. was supported by national grants BFU2015-68741-P from MINECO, PGC2018-099697-B-I00 from MICINN, ‘la Caixa’ Foundation [100010434] under the agreement LCF/PR/HR17/52150016, Marató-TV3 Foundation [20131430]; Catalan Agency for Research and Universities [2017SGR534]; CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech) and it is member of ProteoRed PRB3 consortium which is supported by grant PT17/0019 of the PE I + D + i 2013–2016 from the Instituto de Salud Carlos III (ISCIII), ERDF, and ‘Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya’ [2017SGR595]. A.C. is funded by the MRC Career Development Award (MR/L019434/1) and the ERC Consolidator 101001634 vRNP-capture. We acknowledge the support of the Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa (CEX2020-001049-S, MCIN/AEI /10.13039/501100011033), and the Generalitat de Catalunya through the CERCA Programme. Funding for open access charge: MINECO [PGC2018-099697-B-I00].
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Melanoma RBPome identification reveals PDIA6 as an unconventional RNA-binding protein involved in metastasis

  • Mestre-Farràs, Neus
  • Guerrero Jijon, Santiago Xavier
  • Bley, Nadine
  • Rivero, Ezequiel
  • Coll, Olga
  • Borràs, Eva
  • Sabidó Aguadé, Eduard, 1981-
  • Indacochea Cusirramos, Alberto
  • Casillas-Serra, Carlos
  • Järvelin, Aino I.
  • Oliva Miguel, Baldomero
  • Castello, Alfredo
  • Hüttelmaier, Stefan
  • Gebauer, Fátima
RNA-binding proteins (RBPs) have been relatively overlooked in cancer research despite their contribution to virtually every cancer hallmark. Here, we use RNA interactome capture (RIC) to characterize the melanoma RBPome and uncover novel RBPs involved in melanoma progression. Comparison of RIC profiles of a non-tumoral versus a metastatic cell line revealed prevalent changes in RNA-binding capacities that were not associated with changes in RBP levels. Extensive functional validation of a selected group of 24 RBPs using five different in vitro assays unveiled unanticipated roles of RBPs in melanoma malignancy. As proof-of-principle we focused on PDIA6, an ER-lumen chaperone that displayed a novel RNA-binding activity. We show that PDIA6 is involved in metastatic progression, map its RNA-binding domain, and find that RNA binding is required for PDIA6 tumorigenic properties. These results exemplify how RIC technologies can be harnessed to uncover novel vulnerabilities of cancer cells., N.M. was supported by an FPI fellowship from the Ministry of Economy and Competitiveness; F.G. was supported by national grants BFU2015-68741-P from MINECO, PGC2018-099697-B-I00 from MICINN, ‘la Caixa’ Foundation [100010434] under the agreement LCF/PR/HR17/52150016, Marató-TV3 Foundation [20131430]; Catalan Agency for Research and Universities [2017SGR534]; CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech) and it is member of ProteoRed PRB3 consortium which is supported by grant PT17/0019 of the PE I + D + i 2013–2016 from the Instituto de Salud Carlos III (ISCIII), ERDF, and ‘Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya’ [2017SGR595]. A.C. is funded by the MRC Career Development Award (MR/L019434/1) and the ERC Consolidator 101001634 vRNP-capture. We acknowledge the support of the Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa (CEX2020-001049-S, MCIN/AEI /10.13039/501100011033), and the Generalitat de Catalunya through the CERCA Programme. Funding for open access charge: MINECO [PGC2018-099697-B-I00].
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

RNA-binding proteins in human genetic disease

  • Gebauer, Fátima
  • Schwarzl, Thomas
  • Valcárcel, J. (Juan)
  • Hentze, Matthias W.
RNA-binding proteins (RBPs) are critical effectors of gene expression, and as such their malfunction underlies the origin of many diseases. RBPs can recognize hundreds of transcripts and form extensive regulatory networks that help to maintain cell homeostasis. System-wide unbiased identification of RBPs has increased the number of recognized RBPs into the four-digit range and revealed new paradigms: from the prevalence of structurally disordered RNA-binding regions with roles in the formation of membraneless organelles to unsuspected and potentially pervasive connections between intermediary metabolism and RNA regulation. Together with an increasingly detailed understanding of molecular mechanisms of RBP function, these insights are facilitating the development of new therapies to treat malignancies. Here, we provide an overview of RBPs involved in human genetic disorders, both Mendelian and somatic, and discuss emerging aspects in the field with emphasis on molecular mechanisms of disease and therapeutic interventions., The authors acknowledge funding from the Spanish Ministry of Science and Innovation (MICINN; PGC2018-099697-B-I00 to F.G. and BFU2017-89308-P to J.V.), ‘la Caixa’ Foundation (ID 100010434 under the agreement LCF/PR/HR17/52150016 to F.G.), the Catalan Government (2017SGR534 to F.G. and J.V.) and the ERC (AdvG 670146 to J.V.) as well as the EMBL Partnership, the Severo Ochoa and CERCA Programs
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Ataxin-2, Twenty-four, and Dicer-2 are components of a noncanonical cytoplasmic polyadenylation complex

  • Nadimpalli, Hima Priyanka, 1988-
  • Guitart, Tanit
  • Coll, Olga
  • Gebauer, Fátima
Cytoplasmic polyadenylation is a mechanism to promote mRNA translation in a wide variety of biological contexts. A canonical complex centered around the conserved RNA-binding protein family CPEB has been shown to be responsible for this process. We have previously reported evidence for an alternative noncanonical, CPEB-independent complex in Drosophila, of which the RNA-interference factor Dicer-2 is a component. Here, we investigate Dicer-2 mRNA targets and protein cofactors in cytoplasmic polyadenylation. Using RIP-Seq analysis, we identify hundreds of potential Dicer-2 target transcripts, ∼60% of which were previously found as targets of the cytoplasmic poly(A) polymerase Wispy, suggesting widespread roles of Dicer-2 in cytoplasmic polyadenylation. Large-scale immunoprecipitation revealed Ataxin-2 and Twenty-four among the high-confidence interactors of Dicer-2. Complex analyses indicated that both factors form an RNA-independent complex with Dicer-2 and mediate interactions of Dicer-2 with Wispy. Functional poly(A)-test analyses showed that Twenty-four and Ataxin-2 are required for cytoplasmic polyadenylation of a subset of Dicer-2 targets. Our results reveal components of a novel cytoplasmic polyadenylation complex that operates during Drosophila early embryogenesis., This work was supported by grants from the Spanish Ministry of Science and Innovation (PGC2018-099697-B-I00 and BFU2015-68741) and the Catalan Agency for Research and Universities (2017SGR534). We acknowledge the support of the Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa (CEX2020-001049-S, MCIN/AEI/10.13039/501100011033) and the Generalitat de Catalunya through the CERCA Programme.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

CSDE1 intracellular distribution as a biomarker of melanoma prognosis

  • Indacochea Cusirramos, Alberto
  • Guitart, Tanit
  • Boada, Aram
  • Peg, Vicente
  • Quer, Ariadna
  • Laayouni, Hafid, 1968-
  • Condal, Laura
  • Espinosa, Pablo
  • Manzano Mozo, José Luis
  • Gebauer, Fátima
RNA-binding proteins are emerging as critical modulators of oncogenic cell transformation, malignancy and therapy resistance. We have previously found that the RNA-binding protein Cold Shock Domain containing protein E1 (CSDE1) promotes invasion and metastasis of melanoma, the deadliest form of skin cancer and also a highly heterogeneous disease in need of predictive biomarkers and druggable targets. Here, we design a monoclonal antibody useful for IHC in the clinical setting and use it to evaluate the prognosis potential of CSDE1 in an exploratory cohort of 149 whole tissue sections including benign nevi and primary tumors and metastasis from melanoma patients. Contrary to expectations for an oncoprotein, we observed a global decrease in CSDE1 levels with increasing malignancy. However, the CSDE1 cytoplasmic/nuclear ratio exhibited a positive correlation with adverse clinical features of primary tumors and emerged as a robust indicator of progression free survival in cutaneous melanoma, highlighting the potential of CSDE1 as a biomarker of prognosis. Our findings provide a novel feature for prognosis assessment and highlight the intricacies of RNA-binding protein dynamics in cancer progression., A.I. and P.E. were supported by PhD4MD fellowships from the CRG and the Emerald program (Marie Skłodowska-Curie grant agreement 101034290), respectively. This work was supported by the following grants to F.G.: PGC2018-099697-B-I00 and PID2021-127948NB-I00 from the Spanish Ministry of Science and Innovation (MCIN) funded by MCIN/ AEI /10.13039/501100011033/ and by ERDF; “la Caixa” Foundation (ID 100010434) under the Grant LCF/PR/HR17/52150016; the Catalan Agency for Research and Universities (SGR-Cat-2021-01215) and intramural funds from the CRG on emergent translational research. We acknowledge the support of the Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa (CEX2020-001049-S, MCIN/AEI /10.13039/501100011033) and the Generalitat de Catalunya through the CERCA programme.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Cold-inducible RNA binding protein promotes breast cancer cell malignancy by regulating Cystatin C levels

  • Indacochea Cusirramos, Alberto
  • Guerrero Jijon, Santiago Xavier
  • Ureña, Macarena
  • Araujo, Ferrán
  • Coll, Olga
  • Lleonart, Matilde E.
  • Gebauer, Fátima
Cold-inducible RNA binding protein (CIRBP) is a stress-responsive protein that promotes cancer development and inflammation. Critical to most CIRBP functions is its capacity to bind and posttranscriptionally modulate mRNA. However, a transcriptome-wide analysis of CIRBP mRNA targets in cancer has not yet been performed. Here, we use an ex vivo breast cancer model to identify CIRBP targets and mechanisms. We find that CIRBP transcript levels correlate with breast cancer subtype and are an indicator of luminal A/B prognosis. Accordingly, overexpression of CIRBP in nontumoral MCF-10A cells promotes cell growth and clonogenicity, while depletion of CIRBP from luminal A MCF-7 cells has opposite effects. We use RNA immunoprecipitation followed by high-throughput sequencing (RIP-seq) to identify a set of 204 high confident CIRBP targets in MCF-7 cells. About 10% of these showed complementary changes after CIRBP manipulation in MCF-10A and MCF-7 cells, and were highly interconnected with known breast cancer genes. To test the potential of CIRBP-mediated regulation of these targets in breast cancer development, we focused on Cystatin C (CST3), one of the most highly interconnected genes, encoding a protein that displays tumor suppressive capacities. CST3 depletion restored the effects of CIRBP depletion in MCF-7 cells, indicating that CIRBP functions, at least in part, by down-regulating CST3 levels. Our data provide a resource of CIRBP targets in breast cancer, and identify CST3 as a novel downstream mediator of CIRBP function., Funding: A.I. was supported by a CRG PhD4MD fellowship. F.G. was supported by grants from the Spanish Ministry of Science and Innovation (MICINN, PGC2018-099697-B-I00), “la Caixa” Foundation (ID 100010434) under the agreement LCF/PR/HR17/52150016, the Catalan Agency for Research and Universities (2017SGR534), and the Centre of Excellence Severo Ochoa. M.E.LL. was supported by grants from the Instituto de Salud Carlos III:PI15/01262 and CP03/00101 cofinanced by the European Regional Fund (ERDF) and AECC Funding ref. GC16173720CARR
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

ADAR3 modulates neuronal differentiation and regulates mRNA stability and translation

  • Karlström, Victor
  • Sagredo, Eduardo A.
  • Planells, Jordi
  • Welinder, Charlotte
  • Jungfleisch, Jennifer
  • Barrera Conde, Andrea
  • Engfors, Linus
  • Daniel, Chammiran
  • Gebauer, Fátima
  • Visa, Neus
  • Öhman, Marie
ADAR3 is a catalytically inactive member of the family of adenosine deaminases acting on RNA (ADARs). Here we have investigated its function in the context of the developing mouse brain. The expression of ADAR3 gradually increases throughout embryogenesis and drops after birth. Using primary cortical neurons, we show that ADAR3 is only expressed in a subpopulation of in vitro differentiated neurons, which suggests specific functions rather than being a general regulator of ADAR editing in the brain. The analysis of the ADAR3 interactome suggested a role in mRNA stability and translation, and we show that expression of ADAR3 in a neuronal cell line that is otherwise ADAR3-negative changes the expression and stability of a large number of mRNAs. Notably, we show that ADAR3 associates with polysomes and inhibits translation. We propose that ADAR3 binds to target mRNAs and stabilizes them in non-productive polysome complexes. Interestingly, the expression of ADAR3 downregulates genes related to neuronal differentiation and inhibits neurofilament outgrowth in vitro. In summary, we propose that ADAR3 negatively regulates neuronal differentiation, and that it does so by regulating mRNA stability and translation in an editing-independent manner., Swedish Research Council [dnr.2016-02005, 2018-03823, 2019-03853 to M.Ö., C.D., N.V.]; Carl Trygger's Foundation (to N.V.); V.K. and J.P.R. were supported by the Department of Molecular Biosciences, Wenner-Gren Institute, Stockholm University; E.A.S. was supported by SFO funding from the Faculty of Science at the Stockholm University, O.E. and Edla Johanssons Foundation and Royal Physiographic Society in Lund; Spanish Ministry of Science and Innovation [PGC2018-099697-B-I00 and PID2021-127948NB-I00 to F.G.]; Centro de Excelencia Severo Ochoa [CEX2020-001049-S, MCIN/AEI /10.13039/501100011033]; Generalitat de Catalunya through the CERCA Programme.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

CSDE1 Intracellular Distribution as a Biomarker of Melanoma Prognosis

  • Indacochea, Alberto
  • Guitart, Tanit|||0000-0003-2992-9895
  • Boada, Aram|||0000-0001-9809-5308
  • Peg, Vicente|||0000-0002-5203-6166
  • Quer, Ariadna
  • Laayouni, Hafid|||0000-0003-1297-5078
  • Condal, Laura
  • Espinosa, Pablo|||0000-0003-0692-7301
  • Manzano, José Luís
  • Gebauer, Fátima
RNA-binding proteins are emerging as critical modulators of oncogenic cell transformation, malignancy and therapy resistance. We have previously found that the RNA-binding protein Cold Shock Domain containing protein E1 (CSDE1) promotes invasion and metastasis of melanoma, the deadliest form of skin cancer and also a highly heterogeneous disease in need of predictive biomarkers and druggable targets. Here, we design a monoclonal antibody useful for IHC in the clinical setting and use it to evaluate the prognosis potential of CSDE1 in an exploratory cohort of 149 whole tissue sections including benign nevi and primary tumors and metastasis from melanoma patients. Contrary to expectations for an oncoprotein, we observed a global decrease in CSDE1 levels with increasing malignancy. However, the CSDE1 cytoplasmic/nuclear ratio exhibited a positive correlation with adverse clinical features of primary tumors and emerged as a robust indicator of progression free survival in cutaneous melanoma, highlighting the potential of CSDE1 as a biomarker of prognosis. Our findings provide a novel feature for prognosis assessment and highlight the intricacies of RNA-binding protein dynamics in cancer progression.